Published on | 2 years ago
Programmes Enhancing EU R&IThis report from the Directorate-General for Research and Innovation from the European Commission presents findings from the project “External expertise to support the development of inclusive gender equality in research and innovation (R&I) strategy and contribution to the European Commission Task Force for Equality”. It aims to guide European Commission work with Member States and stakeholders to support the development of inclusive gender equality plans and policies in R&I, in line with the European Union’s commitment to open its R&I gender policies to intersections between gender and other social categories, such as ethnicity, disability, and sexual orientation. The report recommends that policy makers, research funders, and research performing organisations build on prior gender equality actions to develop long term coordinated action to ensure equality and inclusion of marginalised groups in R&I. (from the back cover of the report)
The factsheet 'Towards inclusive gender equality in research and innovation' presents tips and good practices for R&I stakeholders to support the inclusion and equal opportunity of students, researchers and staff from diverse and marginalised backgrounds in European R&I systems
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.